With the global market for consumer health products in excess of $200bn, the sector is expected to continue to grow at a rapid pace driven by increased awareness around personal health, growing preference for over the counter medical remedies over prescription drugs, and the potential for decreased regulation around consumer health products.
Consumer health companies are seeing high valuations in both the public markets and M&A markets. This is largely driven by 2 factors: scarcity of quality brands with a loyal customer base and increased interest from pharmaceutical companies to diversify product portfolios into the consumer health space. Given factors on both the supply of and demand for consumer health products, we expect valuations to remain healthy.
The sector snapshot includes additional information on both the public markets and recent transactions in the consumer health space.